These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32006508)

  • 1. Preparing for yellow fever vaccination.
    Devi S
    Lancet Infect Dis; 2020 Feb; 20(2):172. PubMed ID: 32006508
    [No Abstract]   [Full Text] [Related]  

  • 2. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.
    Barrett ADT
    Vaccine; 2017 Oct; 35(44):5951-5955. PubMed ID: 28366605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Answer to the review from Halstead and Russell "Protective and immunological behavior of chimeric yellow fever dengue vaccine" (DOI 10.1016/j.vaccine.2016.02.004).
    Hadinegoro SR; Arredondo-García JL; Guy B; Bouckenooghe A; Noriega F; Jackson N
    Vaccine; 2016 Aug; 34(36):4273-4. PubMed ID: 27452651
    [No Abstract]   [Full Text] [Related]  

  • 5. Fractional-dose yellow fever vaccination: how much more can we do with less?
    Visser LG
    Curr Opin Infect Dis; 2019 Oct; 32(5):390-393. PubMed ID: 31335440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.
    Kongsgaard M; Bassi MR; Rasmussen M; Skjødt K; Thybo S; Gabriel M; Hansen MB; Christensen JP; Thomsen AR; Buus S; Stryhn A
    Sci Rep; 2017 Apr; 7(1):662. PubMed ID: 28386132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines.
    Juan-Giner A; Warimwe G
    Lancet Infect Dis; 2024 Jun; 24(6):562-564. PubMed ID: 38335975
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D.
    Querec TD; Pulendran B
    Adv Exp Med Biol; 2007; 590():43-53. PubMed ID: 17191376
    [No Abstract]   [Full Text] [Related]  

  • 9. Recovery of yellow fever virus whole genome from an individual with severe vaccine-associated viscerotropic disease.
    Walker HN; Caly L; Savic I; Aziz A; Tran T; Whitley M; Chavada R; Lim CK
    Lancet Microbe; 2024 May; 5(5):e414. PubMed ID: 38219755
    [No Abstract]   [Full Text] [Related]  

  • 10. A qualitatively validated mathematical-computational model of the immune response to the yellow fever vaccine.
    Bonin CRB; Fernandes GC; Dos Santos RW; Lobosco M
    BMC Immunol; 2018 May; 19(1):15. PubMed ID: 29801432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is a dose of 17D vaccine in the current context of Yellow Fever enough?
    Estofolete CF; Nogueira ML
    Braz J Microbiol; 2018; 49(3):683-684. PubMed ID: 29588199
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines and vaccination against yellow fever. WHO position paper -- June 2013.
    Wkly Epidemiol Rec; 2013 Jul; 88(27):269-83. PubMed ID: 23909008
    [No Abstract]   [Full Text] [Related]  

  • 15. Vaccination reshapes the virus-specific T cell repertoire in unexposed adults.
    Pan YG; Aiamkitsumrit B; Bartolo L; Wang Y; Lavery C; Marc A; Holec PV; Rappazzo CG; Eilola T; Gimotty PA; Hensley SE; Antia R; Zarnitsyna VI; Birnbaum ME; Su LF
    Immunity; 2021 Jun; 54(6):1245-1256.e5. PubMed ID: 34004140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.
    Pulendran B
    Nat Rev Immunol; 2009 Oct; 9(10):741-7. PubMed ID: 19763148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yellow fever vaccine.
    Monath TP
    Expert Rev Vaccines; 2005 Aug; 4(4):553-74. PubMed ID: 16117712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus.
    Santos AP; Bertho AL; Dias DC; Santos JR; Marcovistz R
    Mem Inst Oswaldo Cruz; 2005 May; 100(3):331-7. PubMed ID: 16113878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
    Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
    J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vaccine: past, present and future.
    Roukens AH; Visser LG
    Expert Opin Biol Ther; 2008 Nov; 8(11):1787-95. PubMed ID: 18847312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.